Lanean...
Preclinical and Clinical Experience with Dasatinib in Philadelphia Chromosome-Negative Leukemias and Myeloid Disorders
Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph−) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived gro...
Gorde:
| Argitaratua izan da: | Leuk Res |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2008
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428150/ https://ncbi.nlm.nih.gov/pubmed/19013641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.10.001 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|